Collectively our findings demonstrate a critical role for the PtdIns 3-kinase/Akt pathway in macrophage-mediated cytotoxicity against Rituximab-coated B cell lymphomas. The gene discussed is AKT1; the disease is B-cell non-Hodgkin lymphoma.